Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

126 to 150 of 340 results

German pharma price reform sees rebate reduction

German pharma price reform sees rebate reduction

02-01-2014

The new German coalition government has decided to partially revoke the AMNOG (Act on the Reform of the…

GermanyNorthern EuropePharmaceuticalPricingRegulation

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

UK’s NICE backs second indication for Bayer’s Eylea

UK’s NICE backs second indication for Bayer’s Eylea

31-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today announced that…

BayerEuropeEyleaOphthalmicsPharmaceuticalPricingRegeneronRegulation

UK NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

UK NICE draft guidance recommends Ferring’s Firmagon for prostate cancer

27-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence has issued new draft guidance…

EuropeFerring PharmaceuticalsFirmagonOncologyPharmaceuticalPricingRegulationUK

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

27-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsEuropeJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelara InjectionUK

IQWiG view on Roche’s Zelboraf unchanged despite new data

IQWiG view on Roche’s Zelboraf unchanged despite new data

18-12-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has reassessed Swiss drug major…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

IQWiG finds hint of added benefit for Xtandi in prostate cancer

IQWiG finds hint of added benefit for Xtandi in prostate cancer

09-12-2013

In an early benefit assessment under the Act on the German Reform of the Market for Medicinal Products…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalPricingRegulationXtandi

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

Sanofi’s Aubagio gains backing from UK’s NICE

Sanofi’s Aubagio gains backing from UK’s NICE

08-12-2013

In final draft guidance issued on Friday, the UK drugs watchdog the National Institute for Health and…

AubagioEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofiUK

US FDA approval for Gilead's hepatitis C drug Sovaldi

US FDA approval for Gilead's hepatitis C drug Sovaldi

08-12-2013

US antiviral biotech specialist Gilead Sciences says that the Food and Drug Administration has approved…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingRegulationsofosbuvirSovaldi

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

UK’s NICE calls for more info on Sanofi’s Lemtrada in draft guidance

05-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

BiotechnologyEuropeGenzymeLemtradaNeurologicalPricingRegulationSanofiUK

Negative NICE appraisal of Pfizer’s Bosulif for CML

Negative NICE appraisal of Pfizer’s Bosulif for CML

27-11-2013

UK drug watchdog the National Institute for Health and Care Excellence (NICE) has issued final guidance…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRare diseasesRegulation

NICE final guidance gives green light to Lucentis for CNV

NICE final guidance gives green light to Lucentis for CNV

27-11-2013

The UK’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

EuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

UK’s NICE says yes to Alimera’s Iluvien

27-11-2013

In final guidance published this morning by UK drugs watch dog the National Institute for Health and…

Alimera SciencesDiabetesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

IQWiG says no added benefit for Roche’s Erivedge has been proven

IQWiG says no added benefit for Roche’s Erivedge has been proven

18-11-2013

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

ErivedgeEuropeOncologyPharmaceuticalPricingRegulationRoche

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma

12-11-2013

In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

“Generics, Get the Facts Straight” - subject of South Africa workshop

“Generics, Get the Facts Straight” - subject of South Africa workshop

29-10-2013

South Africa’s National Association of Pharmaceutical Manufacturers (NAPM) held a workshop for health…

GenericsPricingRegulationRest of the WorldSouth Africa

Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

18-10-2013

Belgian biotech firm ThromboGenics says that the Final Early Benefit Assessment from the German Federal…

AlconBiotechnologyEuropeJetreaNovartisOphthalmicsPricingRegulationThromboGenics

UK’s NICE reconsiders backing for lymphoma drug Pixuvri

15-10-2013

The UK's National Institute for Health and Care Excellence has launched a second consultation on draft…

Cell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

UK’s NICE thumbs up for Roche drug in rare autoimmune disease in draft guidance

03-10-2013

The UK’s drugs watchdog, the National Institute for Health and Care Excellence (NICE) has published…

EuropeMabTheraOncologyPharmaceuticalPricingRegulationRoche

UK’s NICE issues draft guidance on suite of ovarian cancer drugs

27-09-2013

Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

126 to 150 of 340 results

Back to top